Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Influenza Vaccines Market Size & Growth Forecast 2026–2035, By Segments (Vaccine Type, Indication, Age Group, Route of Administration, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Base Year Value (2025)
USD 8.92 Billion
CAGR (2026-2035)
7.1%
Forecast Year Value (2035)
USD 17.71 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Key Takeaways
- North America region achieved around 41.2% market share in 2025, driven by robust vaccination programs and infrastructure.
- Asia Pacific region will achieve over 8% CAGR between 2026 and 2035, led by increasing immunization drives.
- Achieving 68.6% share in 2025, inactivated segment maintained its lead, sustained by safety profile drives inactivated vaccine dominance.
- In 2025, quadrivalent segment captured 58.8% influenza vaccines market share, propelled by broad protection drives quadrivalent dominance.
- Holding 58.8% share in 2025, the success of adult segment was shaped by high vaccination rates drive adult dominance.
- The top participants in the influenza vaccines market are Sanofi (France), GSK (UK), CSL Seqirus (Australia), AstraZeneca (UK), Vaxart (USA), Pfizer (USA), Moderna (USA), Novavax (USA), Sinovac (China), Bharat Biotech (India).
Market Growth Drivers and Industry Trends
Rising global influenza incidence strengthening annual vaccination demand across adult populationsRecurring influenza outbreaks are making seasonal prevention a more routine healthcare decision for working-age adults, older populations, and individuals with chronic conditions, increasing demand for the influenza vaccines market through repeat annual purchasing rather than one-time adoption. As infection risk becomes more visible through workplace absenteeism, hospital burden, and physician recommendations, adult immunization shifts from being discretionary to expected preventive care, which increases pharmacy-based vaccination, employer-sponsored programs, and primary care channel utilization. This pattern supports market expansion by improving year-over-year revaccination rates and giving manufacturers and providers a more predictable demand base ahead of each flu season.
Government-backed immunization campaigns and surveillance programs supporting vaccine uptake expansion
Public immunization strategies influence the influenza vaccines market by converting clinical guidance into organized delivery, funding, and outreach mechanisms that reduce missed vaccination opportunities. National campaigns, procurement programs, and population targeting help expand access through public clinics, pharmacies, schools, and community health systems, while surveillance programs guide strain selection and seasonal preparedness, allowing health authorities and suppliers to align distribution more effectively. The result is stronger market penetration among priority groups and more consistent uptake patterns, especially where reimbursement support and public communication improve confidence in annual vaccination.
Advancements in mRNA and combination vaccines improving efficacy and manufacturing responsiveness
Platform innovation is reshaping the influenza vaccines market by improving how quickly developers can respond to circulating strains and by strengthening the value proposition of seasonal vaccination for providers and payers. mRNA-based approaches can shorten development and production timelines, which matters in influenza because strain matching and timing directly influence product performance and procurement decisions. Combination vaccines also influence market adoption by reducing the number of separate injections required, making vaccination programs easier to administer and potentially improving compliance among adults who may otherwise defer routine immunization.
Regional Demand Dynamics
Largest Region
North America
56.02% Market Share in 2025
North America held a 56.02% share of the influenza vaccines market in 2025, reflecting the region’s entrenched immunization infrastructure, broad public health purchasing systems, and consistent seasonal vaccination uptake. Leadership is supported by established vaccine procurement and distribution channels across pharmacies, hospitals, clinics, and government programs, which support large-volume annual demand and predictable replenishment cycles. High awareness of influenza prevention, routine recommendations for at-risk populations, and the operational capacity to deliver vaccines quickly ahead of peak flu seasons keep market activity concentrated in the region.
Asia Pacific is projected to expand at an 8.02% CAGR over the forecast period, with growth in the influenza vaccines market being impelled by improving immunization access and rising deployment capacity across large population bases. Expansion is being supported in practice by broader vaccination outreach, increasing healthcare system participation in preventive care, and gradual scaling of supply and administration networks in urban and semi-urban settings. As more healthcare providers incorporate seasonal influenza vaccination into routine care pathways, adoption is accelerating through greater availability and wider reach rather than through a single isolated demand driver.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Nascent |
| Cost-Sensitive Region | Low | Medium | Low | High | High |
| Regulatory Environment | Restrictive | Neutral | Restrictive | Neutral | Neutral |
| Demand Drivers | Strong | Strong | Strong | Moderate | Weak |
| Development Stage | Developed | Developing | Developed | Emerging | Emerging |
| Adoption Rate | High | Medium | High | Low | Low |
| New Entrants / Startups | Moderate | Moderate | Moderate | Sparse | Sparse |
| Macro Indicators | Strong | Stable | Stable | Weak | Weak |
No card data available for this language/report.
Segment Leadership and Growth Trends
Within the influenza vaccines market, Inactivated held the leading position in 2025 with an 87.34% share. Its dominance is sustained by broad established use across immunization programs and routine clinical practice, where providers often rely on vaccine formats with well-developed manufacturing, distribution, and administration pathways. That operating familiarity helps Inactivated vaccines maintain leadership in the influenza vaccines market, especially where consistent supply planning and large-scale seasonal deployment remain central to procurement decisions.
Live Attenuated is the fastest-growing vaccine type in the influenza vaccines market as demand expands for options that better align with evolving vaccination preferences and delivery approaches. Its momentum is underpinned by practical uptake conditions in settings where ease of administration can improve acceptance and support wider immunization reach relative to traditional alternatives. This creates a clearer growth path for Live Attenuated vaccines, particularly where healthcare systems and vaccination campaigns are looking to improve participation without changing the broader seasonal vaccination framework.
Indication Segment Analysis: Quadrivalent (Largest & Fastest-Growing Segment)
By 2025, Quadrivalent accounted for an 82.43% share of the influenza vaccines market, making it both the leading and fastest-growing indication segment. Its strong position reflects the market’s preference for broader strain coverage within a single vaccine approach, which fits well with real-world immunization planning and seasonal procurement requirements. That same practical alignment continues to support growth in the influenza vaccines market, as healthcare providers and public health programs increasingly favor vaccine formats that simplify selection while addressing circulating influenza variation within routine vaccination strategies.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Vaccine Type | Inactivated, Live Attenuated | Inactivated | Live Attenuated |
| Indication | Quadrivalent, Trivalent | Quadrivalent | Quadrivalent |
| Age Group | Pediatric, Adult | Adult | Pediatric |
| Route of Administration | Injection, Nasal Spray | Injection | Nasal Spray |
| Distribution Channel | Hospitals & Pharmacies, Government & Institutional Supply, Other | Hospitals & Pharmacies | Government & Institutional Supply |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
1. Sanofi S.A. (France)
2. GSK plc (United Kingdom)
3. CSL Limited (Australia)
4. AstraZeneca plc (United Kingdom)
5. Pfizer Inc. (United States)
6. Seqirus Ltd. (United Kingdom)
7. Moderna Inc. (United States)
8. Merck & Co. Inc. (United States)
9. Sinovac Biotech Ltd. (China)
10. Viatris Inc. (United States)
The influenza vaccines market is evolving through continuous advancements in vaccine technologies, including cell-based production and next-generation immunization platforms. Manufacturers are strengthening research capabilities to improve vaccine effectiveness and accelerate response to seasonal virus mutations. Investments in scalable production technologies and distribution efficiency are also becoming critical competitive priorities within the influenza vaccines market.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Merck | Nov-25 | Merck entered a definitive agreement to acquire Cidara Therapeutics' long-acting influenza prophylactic candidate, CD388, for approximately $9.2 billion. Currently in Phase 3 development, the asset is positioned to provide prophylactic coverage for high-risk populations, representing a significant strategic investment in the influenza prevention landscape. |
| CSL Seqirus | Dec-25 | CSL Seqirus inaugurated a $1 billion manufacturing facility in Melbourne. This major infrastructure investment is dedicated to the production of cell-based influenza vaccines and antivenoms, substantially increasing regional manufacturing capacity and enhancing the resilience of the global influenza vaccine supply chain. |
| Sanofi | May-24 | Sanofi finalized a strategic partnership with Novavax, involving a $500 million upfront payment to co-commercialize the Novavax COVID-19 vaccine and collaborate on the development of future combination influenza-COVID-19 vaccine candidates utilizing Novavax’s Matrix-M adjuvant technology. |
| Sanofi | Jan-26 | Sanofi discontinued its mRNA seasonal influenza vaccine program. The company remains committed to the influenza market, shifting its strategic focus toward the continued clinical development of an mRNA-based H5 influenza vaccine candidate specifically tailored for pandemic preparedness. |
| Moderna | Dec-25 | Moderna secured up to $54 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the Phase 3 clinical development of its mRNA-based pandemic influenza vaccine candidate, bolstering global efforts to prepare against potential avian influenza outbreaks. |
| CSL Seqirus | Sep-24 | CSL Seqirus was awarded a $121.4 million contract by BARDA to supply adjuvant material sufficient for approximately 40 million pandemic influenza vaccine doses. This procurement strengthens the U.S. government’s strategic stockpile and regional preparedness efforts against potential pandemic-level influenza threats. |
| AstraZeneca | Jan-25 | AstraZeneca cancelled a planned £450 million expansion of its vaccine manufacturing facility in Liverpool. The decision followed a reduction in projected government funding, resulting in the termination of planned production capacity increases for its vaccine portfolio. |
| Pan American Health Organization (PAHO) | May-26 | PAHO reached a regional supply agreement to reserve pandemic influenza vaccine doses for countries across Latin America and the Caribbean. This strategic collaboration enhances regional vaccine distribution logistics and strengthens collective pandemic preparedness frameworks for the Latin American market. |
| Moderna | Mar-26 | Moderna achieved a regulatory milestone as the European Medicines Agency provided support for its combined influenza-COVID mRNA vaccine candidate. This advancement signals progress in the commercialization of next-generation, high-efficacy respiratory vaccines in Europe. |
| European Commission | Feb-26 | The European Commission launched a €225 million pre-commercial procurement initiative focused on developing next-generation influenza vaccines. The program aims to accelerate innovation in vaccine technologies capable of providing broader protection and facilitating faster manufacturing response times to emerging pandemic strains. |
Frequently Asked Questions
What is the current revenue of the influenza vaccines market?
As of 2026 the market size of influenza vaccines is valued at USD 9.47 billion.
What is the forecasted size of the influenza vaccines industry?
Influenza Vaccines Market size is forecast to climb from USD 8.92 billion in 2025 to USD 17.71 billion by 2035 expanding at a CAGR of over 7.1% during 2026-2035.
How are government immunization programs supporting growth in the influenza vaccines market?
Public vaccination campaigns, procurement initiatives, and surveillance programs improve vaccine accessibility, strengthen seasonal preparedness, and expand uptake through coordinated delivery across clinics, pharmacies, schools, and community healthcare settings.
How are vaccine technology advancements influencing the influenza vaccines market?
mRNA platforms and combination vaccines are improving manufacturing responsiveness and simplifying immunization programs, helping providers respond more efficiently to circulating strains while encouraging broader seasonal vaccination participation.
Why do Inactivated vaccines dominate the influenza vaccines market?
Inactivated vaccines accounted for 87.34% of the market in 2025, supported by their established role in immunization programs and well-developed manufacturing, distribution, and administration pathways.
Which indication segment leads growth in the influenza vaccines market?
Quadrivalent vaccines held an 82.43% share in 2025 and are also the fastest-growing segment, benefiting from broader strain coverage and strong alignment with seasonal vaccination planning requirements.
What supports North America's leadership in the influenza vaccines market?
North America captured 56.02% of the market in 2025, backed by strong immunization infrastructure, established procurement systems, and reliable seasonal vaccination demand through multiple healthcare channels.
Why is Asia Pacific emerging as the fastest-growing influenza vaccines market?
Asia Pacific is forecast to grow at an 8.02% CAGR, supported by expanding immunization access, broader vaccination outreach, and increasing healthcare participation in preventive seasonal influenza vaccination programs.
Which companies are driving growth in the influenza vaccines landscape?
Top companies in the influenza vaccines market include Sanofi S.A. (France), GSK plc (United Kingdom), CSL Limited (Australia), AstraZeneca plc (United Kingdom), Pfizer Inc. (United States), Seqirus Ltd. (United Kingdom), Moderna, Inc. (United States), Merck & Co., Inc. (United States), Sinovac Biotech Ltd. (China), Viatris Inc. (United States).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
